Articles tagged with Hepatitis C
Researchers at Rockefeller University have developed a new animal model for hepatitis C using a virus closely related to the human disease, allowing for study of disease progression and immune system response. This breakthrough could accelerate hepatitis C vaccine development and lead to the eradication of the disease.
A new study shows that sofosbuvir and ledipasvir single pill therapy leads to a sustained virological response in 98% of patients with thalassaemia and HCV. The treatment is expected to be limited by drug-to-drug interactions, but offers a significant benefit for these patients.
The EASL Editorial raises concerns about the Cochrane Review's conclusions on Direct Acting Antivirals (DAAs) for Chronic Hepatitis C (HCV), citing a lack of understanding of the disease and its long natural history. Recent studies have shown improvement in quality of life with DAA therapy, highlighting the need for more comprehensive ...
A new drug, sofosbuvir, has been found to significantly reduce liver transplant and mortality rates in patients with advanced stages of liver disease due to hepatitis C. This study involving nearly 1,900 patients showed a 40% reduction in the need for transplants after treatment with sofosbuvir.
The study found that hepatitis C infections among pregnant women increased by 89% from 1.8 to 3.4 per 1,000 live births between 2009 and 2014. Rural counties in Tennessee and West Virginia saw the highest rates of infection, with nearly 8% of pregnant women infected in some counties.
A study found that specific genetic markers can predict which HCV patients are likely to improve with treatment, helping minimize the need for liver transplants. Researchers identified a single nucleotide polymorphism (SNP) in the PNPLA3 gene as a key indicator.
Researchers used GIS and spatial epidemiology to identify areas with highest rates and counts of hepatitis C infections in Massachusetts. The study found hotspots around Boston, New Bedford, and Springfield, highlighting the need for targeted prevention and treatment interventions.
The Canadian Task Force on Preventive Health Care recommends against routine screening for chronic hepatitis C virus (HCV) in low-risk adults due to lack of direct evidence on benefits and harms. The guideline aims to focus healthcare resources on individuals at elevated risk, where treatment is proven to be beneficial.
A Phase 3 study demonstrates that the co-formulation of glecaprevir/pibrentasvir results in a 95% sustained virologic response rate at 12 weeks post treatment in patients with Hepatitis C virus genotype 3. The investigational treatment was well-tolerated and showed comparable safety to sofosbuvir and daclatasvir.
A new study found that 99% of children aged six to 11 with hepatitis C achieved undetectable levels of HCV-RNA 12 weeks after treatment, demonstrating the effectiveness and safety of a direct-acting antiviral regimen. The oral therapy was well-tolerated and did not cause serious adverse events.
A recent study published in Neurology found that people with hepatitis B are 76% more likely to develop Parkinson's disease than those without the virus. Those with hepatitis C have a 51% increased risk. The research linked both viruses to an increased risk of Parkinson's disease, contradicting previous findings on hepatitis B.
A recent study by Indiana University researchers has mapped a key protein of the Zika virus, enabling the analysis of existing drugs and compounds that can disrupt its spread. The study's findings offer hope for finding effective treatments against the disease, which causes birth defects and neurological disorders in infants and adults.
Oral direct-acting antiviral (DAA) regimens produce high sustained virologic response rates for all six hepatitis C virus (HCV) genotypes, making them effective for treating patients with chronic HCV infection. The ease of dosing and safety profile of DAAs provide an opportunity to reduce the burden of hepatitis C in the US.
A recent study found that only a small percentage of baby boomers have been tested for hepatitis C virus (HCV) infection, despite the availability of treatments. The study suggests that increased awareness and innovative strategies, such as state-mandated testing, are needed to improve HCV testing rates among this demographic.
Scientists have developed new HCV vaccination strategies using a model system, aiming to create durable and effective vaccines for all populations. The project, led by Professor Peter Simmonds, will focus on addressing the substantial societal problem of HCV infection.
A study published in the Journal of Substance Abuse Treatment found that black and Hispanic patients, as well as unemployed individuals and those with hepatitis C, are more likely to disengage from treatment programs for opioid dependence. Long-term engagement in therapy is crucial for treating this chronic condition, similar to hypert...
Researchers discovered that hepatitis C virus induces liver cells to produce microRNAs that inhibit interferon production, blunting the body's antiviral defenses. This finding helps explain why interferon treatments fail in many patients, increasing the risk of liver cancer and treatment resistance.
Researchers found that specific IFNL3 and HLA-DPB1 genes are linked to a boost in immunity to hepatitis C after childbirth. Women carrying these genes experienced sharp declines in blood viral levels, improved T-cell activity, and better control of the virus after delivery.
New research from Duke University found that RNA viruses like hepatitis, Zika, and dengue are littered with N6-methyladenosine tags which slow down their ability to infect cells. The study suggests that these chemical tags might regulate the life cycle of these viruses and provide new targets for antiviral drug development.
Nearly all Canadian provinces and territories restrict access to direct-acting antivirals for treating hepatitis C, citing cost concerns. The disease affects over 220,000 Canadians, who often face lengthy delays in receiving treatment.
A new study found that prisons can drive down hepatitis C prevalence and help reach global WHO elimination goals by providing a unique environment for treatment and addressing risk behaviors. Introducing prevention programs in prisons and amongst individuals transitioning back to the community could significantly reduce infections.
The new study debunks myths about treatment efficacy and adherence in people who use drugs, highlighting its benefits in disease elimination. Treatment uptake among people who inject drugs could halve hepatitis C prevalence in 15 years.
A world-first clinical trial found that people who inject drugs can receive safe and effective hepatitis C treatment while on opioid substitution therapy. The results show excellent treatment adherence rates of over 95% and low reinfection rates, contradicting long-held assumptions about drug users' ability to adhere to medication.
A new Brown University study projects that treating 2,000 Rhode Islanders for hepatitis C virus infection per year could reduce cases by 90 percent and prevent over 70 percent of expected liver-related deaths by 2030. The analysis found that doubling the number treated annually could reduce death rates by less than 20 percent.
Researchers investigate how NHS England is hindering access to expensive hepatitis C treatments, citing NICE guidelines and company pricing as key factors. The study reveals a system of rationing and delayed treatment, prompting concerns over patient welfare and the role of drug companies' pricing strategies.
A universal one-time HCV screening based on age can bypass discomfort and democratize preventive care, increasing screenings among all demographics. The screening test detects the virus antibody, with fewer than 1% of targeted baby boomers testing positive, yet helping identify those who benefit from curative treatment.
A study published in PLOS Medicine found that recently developed hepatitis C medicines have a wide range of prices globally, with the US having the highest nominal price. The researchers also calculated that treating the entire HCV infected population in some countries could be as expensive as 190% of the total pharmaceutical expenditure.
Researchers have identified an experimental antiviral drug that slows down Zika virus development in mice. The study suggests the drug may provide protection against Zika-induced symptoms and microcephaly in pregnant women.
A new study published in the American Journal of Preventive Medicine found that excessive alcohol use can accelerate liver damage in people living with hepatitis C. The research suggests that comprehensive approaches to care are needed for these patients, including increased diagnosis and effective interventions to reduce alcohol use.
Researchers found that financing treatment of hepatitis C would not only save lives but ease future costs for Medicare. Expanding screenings and treatment to all patients could generate more than $800 billion in benefits over 20 years. Policymakers must determine how to encourage private insurers to invest in the latest treatments.
Patients with compensated HCV cirrhosis who respond to antiviral therapies have similar survival rates as the general population, according to a new study. The study found that treatment should be given as early as possible to achieve maximum benefit.
A new analysis suggests invoking a little-known 'patent use' law to permit generic versions of patented drugs for government-sponsored insurance programs. This action could allow more patients to access effective drugs like those for hepatitis C at lower costs.
A new study presents data demonstrating that personalized direct-acting antiviral treatment can eradicate the hepatitis C virus from the body in patients who had previously failed treatment. The study identified effective re-treatment combinations for genotype 1 and 3, achieving SVR12 rates of 90% and 100%, respectively.
A new study has demonstrated the efficacy of all-oral treatment regimens in adolescents with hepatitis C virus. The study found that 97% of patients achieved sustained virologic response rates after 12 weeks of treatment, suggesting a promising treatment option for this patient group.
A new study finds that generic direct-acting antiviral treatment for Hepatitis C can deliver high sustained virologic response rates comparable to branded treatments, but at a significantly lower price. The results suggest that generic DAAs could support access to treatment in many countries where it is currently unaffordable.
ABT-493 and ABT-530 achieved 100% sustained virologic response (SVR12) in cirrhotic patients, while non-cirrhotic patients showed a 97% SVR12 rate after eight weeks. This treatment offers hope for genotype 3 patients with heavily scarred livers.
A pilot study found that a direct-acting antiviral treatment over six weeks can effectively cure acute hepatitis C in patients. The treatment resulted in undetectable HCV levels and sustained virologic response after a 12-week follow-up, with side effects including fatigue.
Researchers found that an investigational injectable treatment, RG-101, combined with direct-acting antivirals resulted in high virologic response rates among patients with genotype 1 and 4. The four-week treatment course showed promise in reducing Hepatitis C treatment time.
The World Health Organization (WHO) commended innovative hepatitis testing projects from five countries at The International Liver Congress. These projects showcased new testing models for hepatitis in primary care, community settings, and prisons, highlighting the need to scale up hepatitis testing globally.
A new study suggests that hepatitis C-infected livers can be used for transplants with similar medium- to long-term outcomes as healthy livers. This could reduce the waiting time for liver transplants for people with HCV, with over 15,000 people in the US and 8,500 in Europe currently waiting.
A new triple combination treatment of sofosbuvir/velpatasvir and GS-9857 achieved a high sustained virologic response rate of 99% in patients with HCV genotype 1, 2, 3, 4 and 6. The treatment was generally safe and effective, even in patients who had previously received direct acting antivirals.
A new combination treatment of sofosbuvir, velpatasvir, and GS-9857 demonstrates safety and efficacy in patients with genotype 1 HCV infection. The study achieved high sustained virologic response rates, with 98% of patients responding to the three-drug combination.
A new study demonstrates that community-based non-specialist providers can safely and effectively treat Hepatitis C patients. The study found that 285 out of 304 patients achieved SVR12, with no significant difference between providers in achieving this outcome.
A potentially pan-genotypic combination of ravidasvir and sofosbuvir will be tested in Malaysia and Thailand to treat hepatitis C at a target price of under $300. The treatment, licensed by DNDi, aims to provide an affordable cure for the deadly disease that treats all strains.
New research reveals that heavy drinking after liver transplantation can cause significant damage to newly transplanted livers, leading to severe health issues. Early alcohol assessments and multidisciplinary interventions are crucial to prevent relapse and ensure patient success.
Researchers at Virginia Tech have found a way to potentially track and stop viral outbreaks, including Hepatitis C in humans and plant viruses. By understanding how viruses replicate, they can develop new ways to control infection without causing host toxicity.
A comprehensive review reveals frequent opportunities for HCV exposure in Ghana, including traditional practices like circumcision and home births. The study found a substantial genetic diversity of HCV-2, confirming its long epidemic history in the country.
A recent study found that only 17.4% of ambulatory care nurses reported compliance with all nine standard precautions for infection prevention. The highest rates of compliance were reported for wearing gloves and face masks, but knowledge of hepatitis C virus was variable among participants.
A nationwide study in Taiwan found that people with hepatitis C virus were nearly 30% more likely to develop Parkinson's disease than those without. The study involved over 49,000 participants and followed them for an average of 12 years.
Novel antiviral therapies for hepatitis C have transformed treatment, effectively reducing HCV in over 90% of cases. Enhanced screening and treatment efforts could virtually eliminate the disease within a decade by increasing treatment rates four-fold.
A large clinical trial found that a combination of antiviral medications can eradicate hepatitis C infection in over 90 percent of patients with advanced liver disease. The study showed significant improvements in liver function, even among patients with existing cirrhosis and liver failure.
A team of researchers at the University of Illinois has developed a novel computational approach to accelerate the search for a hepatitis C vaccine. By analyzing the fitness landscape of the virus, they identified optimal formulations targeting viral vulnerabilities that can be attacked by the immune system.
Researchers found that treating patients with expensive new drugs for hepatitis C earlier than usual is worth the cost, despite high prices. Early treatment can save healthcare costs and improve patient quality of life by preventing long-term damage from the disease.
Researchers have developed a novel HCV antigen test system, which significantly improves sensitivity and specificity over current tests. The new test can use urine specimens for one-step screening and diagnosing of HCV infections, making it more convenient and affordable globally.
The O'Neill Institute's new Hepatitis Policy Project aims to address issues and barriers of access to hepatitis C treatment, particularly among baby boomers who often don't know they're infected. The project seeks to support hepatitis C consumer education and advocacy organizations through policy research.
Researchers at the University of Adelaide discovered a family of genes that suppress HCV infection in the liver by blocking viral entry into cells. This natural immune response may lead to new treatments targeting the virus.
The University of Houston will provide free, rapid-HIV testing and counseling to UH students and young people in the surrounding community, with a focus on minority groups. The new grant expands testing to other minority youth and veterans, aiming to increase awareness and early detection of HIV/AIDS and Hepatitis C.
Scientists created a detailed model of the NS3 helicase enzyme, which facilitates viral replication. The study provides insights into how this protein interacts with RNA and could lead to the development of new treatments that target only the hepatitis C virus without harming human cells.
Researchers found marginalized Vancouver residents are dying at 8.29 times the national average, with psychosis and hepatitis C-related liver dysfunction being significant risk factors for mortality. The study highlights the need for improved detection and treatment of these conditions in marginalized populations.
A Yale University study found that nearly one in four patients with chronic hepatitis C are denied initial approval for a drug therapy. The finding reveals factors beyond disease state and medical necessity affecting treatment access, including public insurance status and advanced liver disease.